Program: The Institutional Biosafety Committee (IBC) plays a crucial role in ensuring the safe conduct of research involving the following:
- Creation and use of rDNA or SNAMs.
- Work with all RG2/BSL2 Agents or higher agents, all human, animal and plant pathogens, and non-indigenous plant pathogens or pests.
- Work with biological samples (e.g., animal tissues, fluids, etc.) known or highly suspected to be contaminated with RG2/BSL2 or higher agents.
- Work with non-human primate and human derived materials, including work with human embryonic, fetal, pluripotent, and neural stem cells.
- Work with arthropods.
- Any work with transgenic plants or non-rodent transgenic animals, including purchase of non-rodent transgenic animals.
- Work with acute biological toxins (LD50 ≤ 100 μg/kg body weight), select agents/toxins, or export-controlled toxins.
The federal responsibilities of an IBC primarily originate from the National Institutes of Health (NIH) Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. The NIH guidelines provide guidance for safe research practices in the United States and they are part of the institutional and federal oversight.
Federally Responsibilities
- Oversight of Research Involving Recombinant or Synthetic Nucleic Acids
- Review and Approval of Research Protocols
- Biosafety Levels and Containment Facilities
- Reporting to Federal Agencies
- Risk Assessment and Public Health Protection
- Education and Training
Appointment of Members
The President of the institution delegates the Institutional Official (IO), who is the Vice-President for Research (VPR) the authority to appoint the members of the IBC committee, including the Chair. The IBC committee consists of research personnel, faculty, and members of the community who have the appropriate experience and expertise regarding the use of recombinant or synthetic DNA and the handling of biohazardous materials, agents, and toxins.
Committee Composition
- Chair of the IBC: Expertise in recombinant or synthetic nucleic acid molecules technology and expertise in select agents and toxins, The Chair oversees the IBC and ensures effective functioning of the committee.
- Biosafety Officer (BSO): Provides expertise on biosafety practices, risk assessments, and compliance with safety regulations.
- Researchers/Scientists: At least two members with expertise in creating and using recombinant or synthetic nucleic acid molecules.
- Community Members: At least two non-affiliate members that represent the interest of the surrounding community concerning health and protection of the environment (e.g., officials of state or local public health or environmental protection agencies, members of other local governmental bodies, or persons active in medical, occupational health, or environmental concerns in the community).
- Expert Members: Members with specialized knowledge in fields relevant to biosafety and research, such as microbiology, virology, molecular biology, animal research, or public health.
IBC Member Responsibilities
- Ensure that each IBC submission is reviewed with the highest standard of care according to the federal, state, local and institutional policies and guidelines.
institutional biosafety committee (IBC) 2026
Meetings are scheduled for every 4th Friday of each month. Dates may be subject to change.
Submission DEADLINE is the 1st Friday of each month by 5:00 pm (Mountain time).
Documents must be submitted on eProtocol and received by the deadline to be considered for review.
| Submission DEADLINE on eProtocol * |
IBC Meeting ** |
| January 9, 2026 |
January 23, 2026 |
| February 6, 2026 |
February 27, 2026 |
| March 6, 2026 |
March 27, 2026 |
| April 3, 2026 |
April 24, 2026 |
| May 1, 2026 |
May 22, 2026 |
| June 5, 2026 |
June 26, 2026 |
| July 3, 2026 |
July 24, 2026 |
| August 7, 2026 |
August 28, 2026 |
| September 4, 2026 |
September 25, 2026 |
| October 2, 2026 |
October 23, 2026 |
| November 6, 2026 |
November TBD, 2026 |
| December 4, 2026 |
December TBD, 2026 |
* Subject to change
** 10am-12N, Mountain Time, Virtual, Subject to change